登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Siglec-6 >SI6-H5256

Human Siglec-6 / CD327 Protein, Fc Tag

热销产品推荐:

ACROBiosystems提供针对多种生物标志物靶标的lHC抗体产品,具有:验证充分、质量可靠、灵活授权及免疫组化检测服务支持!

分子别名(Synonym)

SIGLEC6,CD327,CD33L,CD33L1,OBBP1,OB-BP1,CDw327

表达区间及表达系统(Source)

Human Siglec-6, Fc Tag (SI6-H5256) is expressed from human 293 cells (HEK293). It contains AA Gln 16 - Val 320 (Accession # AAH35359).

Predicted N-terminus: Gln 16

Request for sequence

蛋白结构(Molecular Characterization)

Siglec-6 Structure

This protein carries a human IgG1 Fc tag at the C-terminus.

The protein has a calculated MW of 60.3 kDa. The protein migrates as 80-100 kDa under reducing (R) condition, and 130-150 kDa and 250-300 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Siglec-6 SDS-PAGE

Human Siglec-6, Fc Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Siglec-6 ELISA

Immobilized Human Siglec-6, Fc Tag (Cat. No. SI6-H5256) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human Siglec-6 Antibody, Rabbit IgG with a linear range of 0.2-16 ng/mL (Routinely tested).

Protocol

Siglec-6 ELISA

Immobilized Human Siglec-6, Fc Tag (Cat. No. SI6-H5256) at 1 μg/mL (100 μL/well) can bind Human siglec-6/D327 Antibody, Sheep IgG with a linear range of 0.2-8 ng/mL (Routinely tested).

Protocol

 
评论(1)
  1. 619XXXXXXX
  2. 1人赞
  3. The item was expedited very quickly which worked out with our timeline. We are in the process of using the Siglec-6 protein in one of our in-vivo study for immunization. The material itself did not dissolve in complete freund's adjuvant but it was easily made into a fine suspension with the help of some PBS. Overall, I would say the material is easy to work with and the Acro is quick at responding if we have any issues.
  4. 2022-7-12
 
ACRO质量管理体系
 
 

背景(Background)

Sialic acid-binding Ig-like lectin 6 (SIGLEC6) is also known as CD antigen CD327, CD33 antigen-like 1 (CD33L or CD33L1), Obesity-binding protein 1 (OB-BP1). SIGLEC6 belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family, which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. SIGLEC6 mediates sialic-acid dependent binding to cells. SIGLEC6 binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface.

 

前沿进展

Structure of the CD33 Receptor and Implications for the Siglec Family
Vu, Situ, Dai et al
Biochemistry (2025)
Abstract: In the innate immune system, the CD33 receptor modulates microglial activity. Its downregulation promises to slow Alzheimer's disease, and it is already targeted in blood cancers. The mechanism underlying CD33 signaling is unresolved. Starting from the available crystal structure of its extracellular IgV-IgC1 domains, we have assembled a model of the human CD33 receptor by characterizing the oligomerization and structure of IgC1, transmembrane, and cytosolic domains in solution. IgC1 homodimerizes via intermolecular β-strand pairing and packing. In contrast, the 21-residue transmembrane helix of CD33 appears monomeric and straight, with a conserved thin neck and thick belly appearance followed by a positively charged cytosolic patch. The cytosolic domain is dynamically unstructured. Sequence alignment and AlphaFold models indicate that IgC domains in the family of human Siglecs, to which CD33 belongs, are surprisingly variable. Only Siglec-6 is identified to analogously dimerize via IgC1. Our CD33 structural model suggests that the receptor is not signaling via a monomer-dimer shift. Rather, we propose that, aided but also constrained by dimerization, multivalent ligands may concentrate the receptor transmembrane and cytosolic domains sufficiently to trigger colocalization with an activating kinase.
The regulatory role of placental extracellular vesicle on trophoblast and endothelial cell functions
Bai, Li, Guo et al
Front Cell Dev Biol (2025) 13, 1528714
Abstract: Extracellular vesicles (EVs) are cell-derived, membrane-bound vesicles that carry molecular cargo to facilitate communication between cells. During pregnancy, EVs are secreted by the syncytiotrophoblast layer of the placenta villi, where they mediate the functions of resident leukocytes and invading extravillous trophoblasts (EVTs) in the decidua. This study aims to isolate placental EVs (pEVs) from placental explant to examine their regulatory roles on EVT and endothelial cell functions. pEVs were successfully isolated from ex vivo cultured placental explant, which were capable to be internalized by EVTs and endothelial cells. pEVs stimulated the differentiation of trophoblast stem cells (TSCs) and enhanced the migration and invasion abilities of EVTs via CD147 receptor. Conversely, pEVs inhibited the tube formation ability and interleukin-6 (IL-6) secretion of endothelial cells. Together, these findings partially elucidate the role of pEVs during early pregnancy establishment, which may provide insights into pregnancy-related disorders.Copyright © 2025 Bai, Li, Guo, Shang, Lin, Chiu and Lee.
Recent Advances in Our Understanding of Human Inflammatory Dendritic Cells in Human Immunodeficiency Virus Infection
Warner van Dijk, Bertram, O'Neil et al
Viruses (2025) 17 (1)
Abstract: Anogenital inflammation is a critical risk factor for HIV acquisition. The primary preventative HIV intervention, pre-exposure prophylaxis (PrEP), is ineffective in blocking transmission in anogenital inflammation. Pre-existing sexually transmitted diseases (STIs) and anogenital microbiota dysbiosis are the leading causes of inflammation, where inflammation is extensive and often asymptomatic and undiagnosed. Dendritic cells (DCs), as potent antigen-presenting cells, are among the first to capture HIV upon its entry into the mucosa, and they subsequently transport the virus to CD4 T cells, the primary HIV target cells. This increased HIV susceptibility in inflamed tissue likely stems from a disrupted epithelial barrier integrity, phenotypic changes in resident DCs and an influx of inflammatory HIV target cells, including DCs and CD4 T cells. Gaining insight into how HIV interacts with specific inflammatory DC subsets could inform the development of new therapeutic strategies to block HIV transmission. However, little is known about the early stages of HIV capture and transmission in inflammatory environments. Here, we review the currently characterised inflammatory-tissue DCs and their interactions with HIV.
Chronic Spontaneous Urticaria: Current and Emerging Biologic Agents
Bernstein, Bernstein, Lang
Immunol Allergy Clin North Am (2024) 44 (4), 595-613
Abstract: Antihistamine refractory chronic spontaneous urticaria (CSU) has a prevalence of up to 50%. Anti-immunoglobulin E (IgE) therapies have revolutionized management of CSU, yet refractory cases persist, suggesting a role for biologic agents that impact alternative routes of mast cell stimulation independent of cross-linking at FcεR1. This review addresses anti-IgE and Th2-targeted therapies in the management of CSU. In addition, we explore novel treatments targeting alternative pathways of mast cell activation including MAS-related G protein-coupled receptor-X2 and sialic acid-binding immunoglobulin-like lectin-6, inhibiting intracellular signaling via Bruton's tyrosine kinase, and disrupting KIT activation by SCF.Copyright © 2024 Elsevier Inc. All rights reserved.
Showing 1-4 of 53 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Siglec-6靶点信息
英文全称:Sialic acid-binding Ig-like lectin 6
中文全称:唾液酸结合免疫球蛋白样凝集素-6
种类:
上市药物数量:0详情
临床药物数量:2详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定